Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide

Relevance to other NICE programmes

This use of glycopyrronium bromide is not appropriate for referral for a NICE technology appraisal and is not currently planned into any other work programme.

The NICE guideline on cerebral palsy in under 25s recommends considering anticholinergic medication to reduce the severity and frequency of drooling in children and young people with cerebral palsy. The guideline recommends glycopyrronium bromide (oral or by enteral tube), transdermal hyoscine hydrobromide or trihexyphenidyl hydrochloride (for children with dyskinetic cerebral palsy, but only with input from specialist services).

NICE has issued a guideline on spasticity in under 19s. This guideline does not make recommendations on the management of sialorrhoea.

The NICE evidence summary on hypersalivation: oral glycopyrronium bromide discusses the use of glycopyrronium bromide in adults with Parkinson's disease and in adults with schizophrenia and clozapine-induced hypersalivation (unlicensed indications).